Paris - Delayed Quote ? EUR Nanobiotix S.A. (NANO.PA) Follow Compare 4.4800 +0.0620 (+1.40%) At close: October 18 at 5:35 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Paris, France, October 11, 2024Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1 GlobeNewswire ? 9 days ago NBTX NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both na?ve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapySeveral clinical milestones expected over the next 12-18 months including updated data in pancreatic, and head and neck cancer, and initial data in esophageal and lung cancer€66.3 million in cash and cash equivalents as of June 30, 2024, with a cash runway extended i GlobeNewswire ? last month NBTX NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth Dr. Margaret A. Liu, global expert in vaccines, gene therapy, and cancer immunotherapy; chief executive officer of PAX Therapeutics and member of several boardsMs. Anat Naschitz, proven life science investor and entrepreneur; co-founder of OrbiMed Israel PARIS and CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment po GlobeNewswire ? last month NBTX Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming H.C. Wainwright 26th Annual Global Investment conference. Please see below for details of the event. H.C. Wainwright 26th Annual Global Invest GlobeNewswire ? last month NBTX NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Sh GlobeNewswire ? 4 months ago NBTX Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Na?ve or Resistant to Prior anti-PD-1 Therapy Figure 1 Best Change in All Target Lesions Diameter Sum from Baseline Figure 2 Best Change in All Target Lesions Diameter Sum from Baseline Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment48% ORR in evaluable anti-PD-1 na?ve patients (n=25); 28% ORR in evaluable anti-PD-1 resistant patients (n=25) as per RECIST 1.176% DCR in GlobeNewswire ? 4 months ago NBTX NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, at ASCO 2024Following the ASCO presentation, Nanobiotix will host an investor event on Sunday, June 2nd at 12:00 PM EDT / 6:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., May 28, 2 GlobeNewswire ? 4 months ago NBTX NANOBIOTIX to Present at the Jefferies Global Healthcare Conference PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Please see below for details of the event. Jefferies Global Healthcare Conference Date: Wednesday, June GlobeNewswire ? 4 months ago NBTX NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024. First Quarter Financial Updates Cash and Cash Equivalents: Based on the current operating plan and financial projections, Nan GlobeNewswire ? 4 months ago NBTX Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth Updated NBTXR3 Global Development Pipeline Visualization (as of May 21, 2024) *Janssen assumed responsibility for operations in Asia after securing global rights to NBTXR3 in China and Other Asian markets from former Nanobiotix collaborator LianBio. Nanobiotix and Janssen have also aligned to intent to transfer the global sponsorship. Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment GlobeNewswire ? 4 months ago NBTX NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CESTPARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU markets ope GlobeNewswire ? 5 months ago NBTX NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the U.S. Food and Drug Administration (“US FDA”) issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage GlobeNewswire ? 5 months ago NBTX NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung studyMultiple clinical readouts expected in 2024 including immunotherapy combination data from Study GlobeNewswire ? 5 months ago NBTX NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CESTPARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023, GlobeNewswire ? 6 months ago NBTX 11 Best Nanotechnology Stocks To Invest In In this piece, we will take a look at the 11 best nanotechnology stocks to invest in. If you want to skip our introduction to the nanotechnology sector and how it covers a variety of applications ranging from healthcare to consumer technology, then you can skip ahead to read 5 Best Nanotechnology Stocks To Invest […] Insider Monkey ? 6 months ago NANO.PA +1.40% TSM SNPS Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapyConfirmation of injection feasibility and favorable safety profile in completed Phase 1 dose escalation part of the study support potential for later stage development of NBTXR3 for the treatment of patients with inoperable, recurrent NSCLC who are amenable to re-irradiationThe dose expansion part of GlobeNewswire ? 6 months ago NBTX Nanobiotix to Present at Upcoming Investor Conferences in March PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event. Leerink P GlobeNewswire ? 7 months ago NBTX Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on GlobeNewswire ? 8 months ago NBTX Baillie Gifford Bolsters Stake in Nanobiotix SA Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently increased its investment in Nanobiotix SA, a company at the forefront of nanotechnology in cancer treatment. This transaction was executed at a trade price of $5.81 per share, reflecting a 48.18% change in the firm's holdings and a 6.21% ownership in Nanobiotix SA. Despite the significant addition, the trade had a negligible impact on Baillie Gifford (Trades, Portfolio)'s portfolio, with the position accounting for just 0.02% of its total investments. GuruFocus.com ? 8 months ago NBTX ^YH103 Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M mile GlobeNewswire ? 8 months ago NBTX Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is CAC 40 Return NANO.PA CAC 40 YTD -32.53% +0.93% 1-Year -28.09% +8.30% 3-Year -56.50% +13.16%
